For the year ending 2025-06-30, RENB had -$127,767 decrease in cash & cash equivalents over the period. -$7,874,647 in free cash flow.
| Cash Flow | 2025-06-30 |
|---|---|
| Intangible asset impairment | 0 |
| Loss on extinguishment of debt | 0 |
| Goodwill impairment | 170,419,429 |
| Change in fair value of contingent consideration | 11,680,000 |
| Change in fair value of equity securities | 112,149 |
| Net loss | -178,007,489 |
| Depreciation and amortization | 129,095 |
| Non-cash stock-based compensation expense | 3,313,291 |
| Non-cash restricted shares issued for services rendered | 1,946,845 |
| Amortization of discount on note payable | 32,024 |
| Other receivables | -1,153,768 |
| Prepaid expenses/deposits | -1,143,293 |
| Accounts payable | 3,106,181 |
| Other current liabilities | -26,477 |
| Operating leases, net | -16,086 |
| Accrued expenses | 499,330 |
| Net cash used in operating activities | -7,874,647 |
| Purchase of property and equipment | 0 |
| Investment in equity securities | 500,000 |
| Notes receivable prior to acquisition | 0 |
| Cash received from acquisition, net | 0 |
| Net cash used in investing activities | -500,000 |
| Proceeds from exercise of warrants | 0 |
| Repayments of finance agreement | 971,231 |
| Proceeds from private placements | 2,376,181 |
| Proceeds from issuance of promissory notes | 0 |
| Proceeds from notes payable | 6,977,822 |
| Net cash provided by financing activities | 8,382,772 |
| Effect of exchange rates on cash | -135,892 |
| Net increase (decrease) in cash | -127,767 |
| Cash and cash equivalents at beginning of period | 220,467 |
| Cash and cash equivalents at end of period | 92,700 |
Lunai Bioworks Inc. (RENB)
Lunai Bioworks Inc. (RENB)